This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak
by Zacks Equity Research
Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.
Will a 'Huge Tax Cut' Ease Burden for MedTech Players?
by Zacks Equity Research
How is the MedTech industry placed in the wake of the current political conundrum surrounding tax reforms?
Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG
by Zacks Equity Research
Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.
Medtronic (MDT) Tops Q2 Earnings, Misses Revenue Estimate
by Zacks Equity Research
Medtronic's (MDT) year-over-year decrease in revenues of Diabetes Group in Q2 is discouraging.
Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow
by Zacks Equity Research
Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.
Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens
by Zacks Equity Research
Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.
Cardinal Health (CAH) Beats on Q1 Earnings, FY18 View Intact
by Zacks Equity Research
Solid growth at Medical Segment drove Cardinal Health's (CAH) first-quarter results. Product launches and completion of strategic acquisitions in the quarter are major positives.
Key MedTech Trends to Influence Q3 Earnings: BDX, ABC, TFX
by Zacks Equity Research
Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe this season.
United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat
by Zacks Equity Research
United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact
by Zacks Equity Research
Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.
Should You Buy Mazor Robotics (MZOR) As It Hits New High?
by Benjamin Rains
Shares of Mazor Robotics (MZOR) surged over 5% on Wednesday to touch a new all-time high. Now the question for investors is: should you consider buying the surgical robotics maker's stock?
Abbott's Ellipse ICD Receives FDA Approval for MRI Scans
by Zacks Equity Research
Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.
Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm
by Zacks Equity Research
Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.
Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI
by Zacks Equity Research
Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.
Mazor Robotics Gets CE Mark for Surgical Assurance Platform
by Zacks Equity Research
Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.
Mazor Robotics' CE Mark for Mazor X Platform to Drive Orders
by Zacks Equity Research
Mazor Robotics and Medtronic will now be able to market and sell the Mazor X Surgical Assurance Platform in countries that recognize the CE Mark.
Medtronic Advances in Pain Therapy With U.S. Intellis Launch
by Zacks Equity Research
We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.
Medtronic (MDT) Down 2.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Medtronic Launches StealthStation Technology, Expands in ENT
by Zacks Equity Research
Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.
Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag
by Zacks Equity Research
Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.
MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails
by Zacks Equity Research
Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.
The Zacks Analyst Blog Highlights: Starbucks, Medtronic, Monsanto, Halliburton and Sprint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Starbucks, Medtronic, Monsanto, Halliburton and Sprint
Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level
by Zacks Equity Research
With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.